Exide Technologies (Nasdaq: XIDE) reported earnings on Thursday. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended June 30 (Q1), Exide Technologies missed estimates on revenues and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue contracted and GAAP loss per share grew.

Margins dropped across the board.

Revenue details
Exide Technologies reported revenue of $693.4 million. The eight analysts polled by S&P Capital IQ predicted net sales of $742.3 million on the same basis. GAAP reported sales were 6.9% lower than the prior-year quarter's $745.1 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at -$1.39. The five earnings estimates compiled by S&P Capital IQ predicted -$0.01 per share. GAAP EPS were -$1.38 for Q1 compared to -$0.07 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 13.6%, 210 basis points worse than the prior-year quarter. Operating margin was 0.1%, 180 basis points worse than the prior-year quarter. Net margin was -15.4%, 1,470 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $774.8 million. On the bottom line, the average EPS estimate is -$0.02.

Next year's average estimate for revenue is $3.11 billion. The average EPS estimate is -$1.01.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 414 members rating the stock outperform and 14 members rating it underperform. Among 72 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 68 give Exide Technologies a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Exide Technologies is outperform, with an average price target of $4.93.